OBJECTIVE:: This study describes recent trends and patterns in antipsychotic treatment of privately insured children aged 2 through 5 years. METHOD:: A trend analysis is presented of antipsychotic medication use (1999-2001 versus 2007) ...

Days before a Food and Drug Administration (FDA) advisory committee reviewed the safety concerns about antipsychotic drug use in pediatric patients, two additional antipsychotics, quetiapine and olanzapine, were approved by the agency ...

Johnson & Johnson made plans to reach $302 million in geriatric sales for its antipsychotic Risperdal just months after federal regulators said the company falsely claimed the drug was safe and effective with the elderly, according to ...

A trial under way in New Jersey has the potential to shine a spotlight on the antipsychotic drugs given to veterans returning from Iraq and Afghanista.

A perilous disconnect: antipsychotic drug use in very young children. J Am Acad Child Adolesc Psychiatry. 2010 Jan;49(1):3-6. Authors: Egger H. PMID: 20215919 [PubMed - in process]. March 11th, 2010 | Category: J Am Acad Child Adolesc ...

Massachusetts joins the cadre of states spending funds on antipsychotics for nursing home patients who probably shouldn't be given the drugs at all, the Boston Globe reports. According to data collected by the Centers for Medicare and ...

An important warning about atypical, or second-generation, antipsychotic drugs and a connection to increased risk for diabetes and hyperglycemia didn't make it to primary care physicians, according to a new study in the Archives of ...

In the face of all this bad news, how can it be that a recent study of over 16000 nursing home admissions found that 29% received at least one antipsychotic over the course of a year? Of these, just about one-third had no identified ...

BOSTON — Federal officials say nearly 2500 Massachusetts nursing home residents were given powerful antipsychotic drugs last year that were not intended or recommended for their medical condition. The Boston Globe reports that data ...

US sales in 2009 of AstraZeneca's blockbuster antipsychotic Seroquel increased with the promotion of the extended release version of the drug now approved for MDD, originally created for treatment of schizophrenia. ...